A detailed history of Vanguard Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,113,384 shares of PCRX stock, worth $145 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,113,384
Previous 5,098,424 0.29%
Holding current value
$145 Million
Previous $172 Million 13.14%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$27.7 - $35.48 $414,392 - $530,780
14,960 Added 0.29%
5,113,384 $149 Million
Q4 2023

Feb 14, 2024

BUY
$26.32 - $34.31 $3.73 Million - $4.86 Million
141,719 Added 2.86%
5,098,424 $172 Million
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $134,777 - $176,115
4,393 Added 0.09%
4,956,705 $152 Million
Q2 2023

Aug 14, 2023

SELL
$36.12 - $47.5 $935,724 - $1.23 Million
-25,906 Reduced 0.52%
4,952,312 $198 Million
Q1 2023

May 15, 2023

BUY
$35.53 - $43.38 $1.88 Million - $2.3 Million
53,023 Added 1.08%
4,978,218 $203 Million
Q4 2022

Feb 10, 2023

BUY
$38.19 - $57.45 $2.17 Million - $3.26 Million
56,750 Added 1.17%
4,925,195 $190 Million
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $2.83 Million - $3.25 Million
55,188 Added 1.15%
4,868,445 $259 Million
Q2 2022

Aug 12, 2022

BUY
$51.49 - $81.64 $6.44 Million - $10.2 Million
125,138 Added 2.67%
4,813,257 $281 Million
Q1 2022

May 13, 2022

BUY
$60.03 - $76.49 $1.33 Million - $1.7 Million
22,164 Added 0.48%
4,688,119 $358 Million
Q4 2021

Feb 14, 2022

SELL
$47.97 - $62.21 $4.9 Million - $6.35 Million
-102,108 Reduced 2.14%
4,665,955 $281 Million
Q3 2021

Nov 12, 2021

BUY
$54.64 - $61.3 $2.36 Million - $2.64 Million
43,134 Added 0.91%
4,768,063 $267 Million
Q2 2021

Aug 13, 2021

BUY
$59.18 - $69.99 $280 Million - $331 Million
4,724,929 New
4,724,929 $287 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.3B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.